Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.59 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 5/20 | 0.50 |
| ▸ | MMP9 | P14780 | 5/20 | 0.50 |
| ▸ | MMP8 | P22894 | 5/20 | 0.50 |
| ▸ | MMP13 | P45452 | 5/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | PRSS12 | P56730 | 2/20 | 0.44 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11957168 | 0.91 | HDAC6 (0.59) | HDAC6MMP2MMP9MMP8MMP13 | |
| SCHEMBL3099694 | 0.90 | HDAC6 (0.56) | HDAC6MMP2MMP9MMP8MMP13 | |
| SCHEMBL11949010 | 0.90 | SIRT2 (0.55) | HDAC6SIRT2MMP2MMP9MMP8 | |
| SCHEMBL11949042 | 0.90 | HDAC6 (0.53) | HDAC6SIRT2MMP2MMP9MMP8 | |
| SCHEMBL11949007 | 0.89 | MMP2 (0.58) | HDAC6SIRT2MMP2MMP9MMP8 | |
| SCHEMBL11949024 | 0.88 | PRSS12 (0.56) | HDAC6SIRT2MMP2MMP9MMP8 | |
| SCHEMBL11949038 | 0.87 | HDAC6 (0.55) | HDAC6HDAC3HDAC1HDAC8HPSE | |
| SCHEMBL11948988 | 0.85 | MMP2 (0.56) | HDAC6SIRT2MMP2MMP9MMP8 | |
| SCHEMBL11949039 | 0.84 | NR4A2 (0.55) | HDAC6MMP2MMP9MMP8MMP13 | |
| SCHEMBL11949020 | 0.82 | PRSS12 (0.61) | HDAC6CHEK2PRSS12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232410-B2 | Benzimidazoles and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256203-A1 | BENZIMIDAZOLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TBCD, TBC1D5, CFTR | HDAC6 47/4885SIRT2 1501/4885MMP2 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.